2-[4-Hydroxy-5-[5-hydroxy-6-(hydroxymethyl)-3,4-bis[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl]oxy-6-(hydroxymethyl)-2-[[7,9,13-trimethyl-6-[3-methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutyl]-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-6-en-16-yl]oxy]oxan-3-yl]oxy-6-methyloxane-3,4,5-triol
| Internal ID | 4b232c74-b254-429e-8f47-0e710f2382f3 |
| Taxonomy | Lipids and lipid-like molecules > Steroids and steroid derivatives > Steroidal glycosides > Steroidal saponins |
| IUPAC Name | 2-[4-hydroxy-5-[5-hydroxy-6-(hydroxymethyl)-3,4-bis[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl]oxy-6-(hydroxymethyl)-2-[[7,9,13-trimethyl-6-[3-methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutyl]-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-6-en-16-yl]oxy]oxan-3-yl]oxy-6-methyloxane-3,4,5-triol |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C61H100O30/c1-22(19-79-54-47(76)44(73)41(70)34(16-62)85-54)6-9-32-23(2)37-33(84-32)15-29-27-8-7-25-14-26(10-12-60(25,4)28(27)11-13-61(29,37)5)83-58-52(90-57-48(77)43(72)38(67)24(3)82-57)49(78)50(36(18-64)87-58)88-59-53(91-56-46(75)40(69)31(66)21-81-56)51(42(71)35(17-63)86-59)89-55-45(74)39(68)30(65)20-80-55/h22,24-31,33-59,62-78H,6-21H2,1-5H3 |
| InChI Key | CNGHCVZOTCCMMB-UHFFFAOYSA-N |
| Popularity | 0 references in papers |
| Molecular Formula | C61H100O30 |
| Molecular Weight | 1313.40 g/mol |
| Exact Mass | 1312.62994177 g/mol |
| Topological Polar Surface Area (TPSA) | 464.00 Ų |
| XlogP | -3.80 |
| Atomic LogP (AlogP) | -5.05 |
| H-Bond Acceptor | 30 |
| H-Bond Donor | 17 |
| Rotatable Bonds | 19 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.6879 | 68.79% |
| Caco-2 | - | 0.8749 | 87.49% |
| Blood Brain Barrier | - | 0.6500 | 65.00% |
| Human oral bioavailability | - | 0.8000 | 80.00% |
| Subcellular localzation | Mitochondria | 0.6925 | 69.25% |
| OATP2B1 inhibitior | - | 1.0000 | 100.00% |
| OATP1B1 inhibitior | + | 0.8539 | 85.39% |
| OATP1B3 inhibitior | + | 0.9297 | 92.97% |
| MATE1 inhibitior | - | 0.9412 | 94.12% |
| OCT2 inhibitior | - | 0.5500 | 55.00% |
| BSEP inhibitior | + | 0.9098 | 90.98% |
| P-glycoprotein inhibitior | + | 0.7425 | 74.25% |
| P-glycoprotein substrate | + | 0.7018 | 70.18% |
| CYP3A4 substrate | + | 0.7534 | 75.34% |
| CYP2C9 substrate | - | 0.8018 | 80.18% |
| CYP2D6 substrate | - | 0.8244 | 82.44% |
| CYP3A4 inhibition | - | 0.9320 | 93.20% |
| CYP2C9 inhibition | - | 0.9177 | 91.77% |
| CYP2C19 inhibition | - | 0.9166 | 91.66% |
| CYP2D6 inhibition | - | 0.9363 | 93.63% |
| CYP1A2 inhibition | - | 0.9075 | 90.75% |
| CYP2C8 inhibition | + | 0.7359 | 73.59% |
| CYP inhibitory promiscuity | - | 0.9284 | 92.84% |
| UGT catelyzed | + | 1.0000 | 100.00% |
| Carcinogenicity (binary) | - | 0.9900 | 99.00% |
| Carcinogenicity (trinary) | Non-required | 0.5732 | 57.32% |
| Eye corrosion | - | 0.9908 | 99.08% |
| Eye irritation | - | 0.9010 | 90.10% |
| Skin irritation | - | 0.5215 | 52.15% |
| Skin corrosion | - | 0.9467 | 94.67% |
| Ames mutagenesis | - | 0.7215 | 72.15% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.8382 | 83.82% |
| Micronuclear | - | 0.8900 | 89.00% |
| Hepatotoxicity | - | 0.8000 | 80.00% |
| skin sensitisation | - | 0.9208 | 92.08% |
| Respiratory toxicity | + | 0.7111 | 71.11% |
| Reproductive toxicity | + | 0.8556 | 85.56% |
| Mitochondrial toxicity | + | 0.5250 | 52.50% |
| Nephrotoxicity | - | 0.9828 | 98.28% |
| Acute Oral Toxicity (c) | I | 0.8055 | 80.55% |
| Estrogen receptor binding | + | 0.8415 | 84.15% |
| Androgen receptor binding | + | 0.7362 | 73.62% |
| Thyroid receptor binding | + | 0.5673 | 56.73% |
| Glucocorticoid receptor binding | + | 0.7126 | 71.26% |
| Aromatase binding | + | 0.6950 | 69.50% |
| PPAR gamma | + | 0.7940 | 79.40% |
| Honey bee toxicity | - | 0.5819 | 58.19% |
| Biodegradation | - | 0.7500 | 75.00% |
| Crustacea aquatic toxicity | - | 0.5800 | 58.00% |
| Fish aquatic toxicity | + | 0.9074 | 90.74% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 97.45% | 91.11% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 97.40% | 96.09% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 95.79% | 97.25% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 95.09% | 97.09% |
| CHEMBL226 | P30542 | Adenosine A1 receptor | 94.07% | 95.93% |
| CHEMBL1937 | Q92769 | Histone deacetylase 2 | 89.19% | 94.75% |
| CHEMBL237 | P41145 | Kappa opioid receptor | 89.01% | 98.10% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 88.99% | 100.00% |
| CHEMBL2782 | P35610 | Acyl coenzyme A:cholesterol acyltransferase 1 | 88.90% | 91.65% |
| CHEMBL6136 | O60341 | Lysine-specific histone demethylase 1 | 88.81% | 95.58% |
| CHEMBL218 | P21554 | Cannabinoid CB1 receptor | 88.71% | 96.61% |
| CHEMBL1994 | P08235 | Mineralocorticoid receptor | 87.79% | 100.00% |
| CHEMBL233 | P35372 | Mu opioid receptor | 87.38% | 97.93% |
| CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 87.32% | 97.29% |
| CHEMBL2955 | O95136 | Sphingosine 1-phosphate receptor Edg-5 | 87.10% | 92.86% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 87.07% | 89.00% |
| CHEMBL2996 | Q05655 | Protein kinase C delta | 86.51% | 97.79% |
| CHEMBL2635 | P51452 | Dual specificity protein phosphatase 3 | 86.47% | 94.00% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 85.73% | 95.89% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 85.72% | 94.45% |
| CHEMBL4581 | P52732 | Kinesin-like protein 1 | 85.68% | 93.18% |
| CHEMBL325 | Q13547 | Histone deacetylase 1 | 85.50% | 95.92% |
| CHEMBL3714130 | P46095 | G-protein coupled receptor 6 | 85.09% | 97.36% |
| CHEMBL2288 | Q13526 | Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | 84.93% | 91.71% |
| CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 84.72% | 86.33% |
| CHEMBL3880 | P07900 | Heat shock protein HSP 90-alpha | 84.32% | 96.21% |
| CHEMBL206 | P03372 | Estrogen receptor alpha | 84.23% | 97.64% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 84.16% | 96.47% |
| CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 83.55% | 96.38% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 83.33% | 92.88% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 83.30% | 95.89% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 82.35% | 96.90% |
| CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 81.16% | 91.24% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 81.10% | 90.71% |
| CHEMBL3476 | O15111 | Inhibitor of nuclear factor kappa B kinase alpha subunit | 80.90% | 95.83% |
| CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 80.48% | 96.00% |
| CHEMBL3004 | P33527 | Multidrug resistance-associated protein 1 | 80.38% | 96.37% |
| CHEMBL4618 | P09960 | Leukotriene A4 hydrolase | 80.31% | 97.86% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 80.20% | 93.56% |
| CHEMBL2095194 | P08709 | Coagulation factor VII/tissue factor | 80.18% | 99.17% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 80.01% | 93.10% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| Tribulus terrestris |
| PubChem | 75299197 |
| LOTUS | LTS0179987 |
| wikiData | Q104965747 |